By Jasmine Li
Pulse Biosciences reported positive preliminary results from its clinical study of a treatment for benign thyroid nodules.
The Miami-based company's Nanosecond Pulsed Field Ablation technology reduced nodule sizes on average by more than 50%, it said on Thursday.
The 30-patient feasibility study also found that the technology provided symptomatic relief within the first month of treatment, and showed no evidence of residual fibrosis or scarring, the company said.
These results suggest that nano-PFA energy can provide symptomatic relief to patients with benign thyroid nodules across the first month after the treatment, Chief Executive Burke Barrett said.
The company intends to commence a pivotal trial in mid-2025 designed to support a specific labeling indication to commercialize the system in the U.S., Barrett said.
Write to Jasmine Li at jasmine.li@wsj.com
(MORE TO FOLLOW) Dow Jones Newswires
October 31, 2024 15:12 ET (19:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。